WELCOME TO PHT PHARMA
With significant expertise in the development and manufacture of complex small molecules, PHT provides support for projects at all scales of manufacturing, from milligrams to multi-tons.
Operating from out state-of-the art facility in Nantong, China our experienced process R&D team supports projects from early proof of concept through delivery of the first non-cGMP batch for toxicology studies or IND-enabling activities.
Following our well-established technology transfer process, projects progress smoothly to our cGMP CDMO facility in Shangyu, China, enabling continued development, scale-up, and reliable production through to commercial quantities.
Partner with our experts to accelerate route development, optimize scalability, and transition seamlessly into cGMP manufacturing with full technical transparency, regulatory-ready documentation and dependable project governance.
Our Principles
PHT is a company built on three principles: people, honesty and trust.
Expertise
We invest in a high-quality, highly skilled workforce to better understand the needs of our pharmaceutical customers.
Transparency
Trusted Globally
Our Principles
PHT is a company built on three principles: people, honesty and trust.
Expertise
We invest in a high-quality, highly skilled workforce to better understand the needs of our pharmaceutical customers.
Transparency
Trusted Globally
Our CRO team supports discovery programs from concept to clinic. We partner with biotech and pharmaceutical companies on hit identification through to lead optimization, delivering high-quality compound synthesis and clear, data-led insights. With flexible resourcing and close collaboration, we help you prioritize effectively and accelerate program progress.
Our Process R&D team develops scalable, efficient and cost-effective manufacturing routes. From route scouting and optimization to impurity control and scale-up, we deliver robust, transferable processes. Using data-driven approaches and strong analytical support, we ensure reliable progression from early development to larger-scale manufacture.
As a small-molecule CDMO, we provide integrated development and manufacturing from process R&D to cGMP supply. We deliver safe, scalable processes supported by strong analytical expertise and quality systems. With experienced project leadership and flexible capabilities, we ensure reliable delivery from development through to market.
PHT balances growth with environmental responsibility, reducing CO₂ emissions by over 300MT in 2025 and targeting a further 450MT reduction in 2026 while expanding our pharmaceutical business. We have invested in advanced wastewater treatment facilities to ensure no harmful discharge, alongside commitments to SBTi targets and industry best practice.
Through cleaner, more efficient chemistry and process optimization, we reduce energy use, minimise waste and support more sustainable pharmaceutical manufacturing at scale.
